BOOST Pharma develops BT-101, a mesenchymal stem cell therapy intended for children born with osteogenesis imperfecta, a severe inherited condition also known as brittle bone disease. BT-101 is designed for early intervention in infants to address the underlying cause of the disease and reduce fracture frequency. The programme has FDA Rare Paediatric Disease designation and orphan drug designation in Europe and the US, and the company has completed an FDA pre-IND meeting ahead of a planned pivotal study.